

Advanced Prostate Cancer Metastatic Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Activity of
RO7656594 In Participants With Advanced or Metastatic Prostate
Cancer

Trial Status Recruiting	Trial Runs In 3 Countries	Trial Identifier NCT05800665 2023-504013-68-00 GO44537
-----------------------------------	-------------------------------------	---

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

Genentech, Inc. Sponsor	Phase 1 Phase
NCT05800665 2023-504013-68-00 GO44537 Trial Identifiers	

Eligibility Criteria:

Gender Male	Age ≥18 Years	Healthy Volunteers No
-----------------------	-------------------------	---------------------------------